Celltrion to expand COVID-19 testing portfolio to include Ag & Ab testing kits
Singapore, June 16 -- Celltrion Group has announced plans to expand its diagnostic portfolio for SARS-CoV-2, the virus causing COVID-19, in its efforts to improve access to COVID-19 testing and help prevent the further spread of coronavirus infection worldwide.
Celltrion has completed development of a point-of-care antigen testing (POCT) kit for COVID-19 together with South Korean healthcare company BBB, which specialises in blood testing and lab-on-a-chip technology.
The POCT kit is a portable and highly sensitive device for use in rapid point of care testing to support early detection of COVID-19 positive patients in clinical settings.
Promising early results for a prototype of Celltrion's POCT kit for COVID-19 showed more than 95% s...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.